Homepage >>>

    Municipal Market Weekly Commentary – JOE MYSAK

    Johnson & Johnson’s Launch of Invokana Bodes Well for SGLT-2 Class

    Compiled by Sam Fazeli, Bloomberg Industries and Elizabeth Krutoholow Johnson & Johnson’s newly launched diabetes drug Invokana appears to have fairly strong uptake, according to data from inThought Research. This may bode well for other agents in the new SGLT-2 class, said Christopher Martin, Senior Principal, Symphony Health Solutions in a webcast with Bloomberg Industries’ [...]

    Lack of RDP Unlikely Threat to Biogen’s Tecfidera EU Patents

    By Asthika Goonewardene, Bloomberg Industries, and Aude Gerspacher, Bloomberg Law   The EU regulatory body’s denial of regulatory data protection (RDP) does not impact the strength of Biogen’s European patents, Aude Gerspacher, a Bloomberg Law writer and editor with more than 10 years’ experience as a patent attorney said in a call with Bloomberg Industries’ [...]

    RBS Exit Highlights Cost Challenge for Issuers

    Declining profits and tightening regulation of structured products are prompting banks from Royal Bank of Scotland Group Plc to Rabobank Groep to quit the business. RBS last week became the third European bank to close its structured products operation for retail investors since March, citing high capital costs and expenses for the securities. Dutch lender [...]

    Fashion and Apparel Industry Prefers Out-of-Court Restructurings

    Guest Commentary by Allan Ellinger In 2010 and 2011, retail was among the top five defaulting sectors, according to a March 2013 report published by analysts at Fitch. Last year, this segment of the economy appeared to be doing better: It did not make it into top five defaulting sectors of the rating agency’s U.S. high yield default index. Click here to continue reading the full commentary. _____________________________________________________ [...]

    June 2013 FOMC Meeting Preview

    Second Generation TKIs Will Require Survival Data to Supplant Gleevec in Front-Line CML

    by Elizabeth Krutoholow Newly approved therapeutics for chronic myelogenous leukemia (CML) or so-called second generation tyrosine kinase inhibitors (TKIs) like Ariad’s Iclusig and Pfizer’s Bosulif will require data showing survival improvements before clinicians adopt them in the front-line setting, according to Dr. Elias Jabbour, Associate Professor in the Department of Leukemia, at The University of Texas MD Anderson Cancer Center. Read more >>> 

    What’s Causing the Drop in Corporate Bankruptcies?

    Take a risk free 30 day trial to Bloomberg’s Bankruptcy newsletter - click here.

    Meredith Whitney Joins ‘Fleeing the Coasts’ Club

    Press play to start the video. After the introduction, the book review will automatically open at the end. Take a free 30 day  trial to our Municipal Market newsletter here.

    EU Lemtrada Decision Key to Genzyme CVR Holders

    By Andrew Berens, MD Senior Healthcare Analyst, Bloomberg Industries Sanofi’s multiple sclerosis (MS) drug Lemtrada may soon be recommended for European approval, where revenue is especially important to holders of Genzyme contingent value rights linked to the drug’s success. Read more >>>

1 2 3 37 38 39 40 41 42 43 72 73 74

Bloomberg BRIEF Newsletters